Sunday, June 21, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 159 of 1,261
  1. US 11807638

    5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases

    Enliven Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  2. US 11807674

    Hepcidin analogues and uses thereof

    Protagonist Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  3. US 11807853

    Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  4. US 11807682

    M971 chimeric antigen receptors

    The United States of America, as represented by the Secretary, Department of Heath and Human Services · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  5. US 11807646

    4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19)

    ALMAC DISCOVERY LIMITED · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  6. US 11806432

    Compositions, methods and uses for thermally stable multi-targeted antigens

    The Regents of the University of Colorado, a Body Corporate · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  7. US 11806398

    Citrate buffered VEGF antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  8. US 11806336

    Methods and compositions for treatment of epileptic disorders

    OVID THERAPEUTICS INC. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  9. US 11806318

    Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  10. US 11806360

    Compositions and methods for treating transthyretin (TTR) mediated amyloidosis

    Alnylam Pharmaceuticals, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  11. US 11806367

    Methods of treating lysosomal disorders

    The Regents of the University of California · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  12. US 11807636

    IRAK degraders and uses thereof

    Kymera Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  13. US 11806369

    Exosomes and miRNA to treat glaucoma

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  14. US 11806334

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  15. US 11806337

    Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  16. US 11806353

    Methods of treating liver disorders or lipid disorders with a THR-beta agonist

    Madrigal Pharmaceuticals, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  17. US 11807629

    Polymorphs of Selinexor

    Karyopharm Therapeutics Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  18. US 11806385

    Biomarkers for monitoring immune transformation

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  19. US 11806389

    Compositions and methods for treating central nervous system injury

    The United States Government as Represented by The Department of Veteran Affairs · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  20. US 11806400

    Injectable ibuprofen formulation

    Cumberland Pharmaceuticals Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  21. US 11807605

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  22. US 11806408

    Methods and compositions for treating cone-rod retinal dystrophy

    Editas Medicine, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  23. US 11806429

    Film formulations containing dexmedetomidine and methods of producing them

    BioXcel Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  24. US 11806406

    Virus-like particle conjugates for diagnosis and treatment of tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.